116174-33-5Relevant academic research and scientific papers
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3
Leclerc, Véronique,Ettaoussi, Mohamed,Rami, Marouan,Farce, Amaury,Boutin, Jean Albert,Delagrange, Philippe,Caignard, Daniel-Henri,Renard, Pierre,Berthelot, Pascal,Yous, Sa?d
experimental part, p. 1622 - 1629 (2011/05/04)
Naphthalenic analogs of MCA-NAT (5-methoxycarbonylamino-N-acetyltryptamine) have been synthesized and evaluated as melatonin receptor ligands. Introduction of a methoxycarbonylamino substituent at the C-7 position of the naphthalenic nucleus yields MTsub
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carbo xylic acid as a potent hypoglycemic and hypolipidemic agent
Pingali, Harikishore,Jain, Mukul,Shah, Shailesh,Basu, Sujay,Makadia, Pankaj,Goswami, Amitgiri,Zaware, Pandurang,Patil, Pravin,Godha, Atul,Giri, Suresh,Goel, Ashish,Patel, Megha,Patel, Harilal,Patel, Pankaj
scheme or table, p. 5586 - 5590 (2009/06/18)
A series of novel 1,3-dioxane-2-carboxylic acid derivatives containing alkyl chain tether and substituted phenyl group as a lipophilic tail have been prepared as agonists of PPARα and γ. c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carbo xylic acid 13c exhibited potent hypoglycemic and lipid lowering activity with high oral bioavailability in animal models.
Evaluation of the efficiency of the photocatalytic one-electron oxidation reaction of aromatic compounds adsorbed on a TiO2 surface
Tachikawa, Takashi,Yoshida, Akihiro,Tojo, Sachiko,Sugimoto, Akira,Fujitsuka, Mamoru,Majima, Tetsuro
, p. 5345 - 5353 (2007/10/03)
The TiO2 photocatalytic one-electron oxidation mechanism of aromatic sulfides with a methylene bridging group (-(CH2) n-, n = 0-4) between the 4-(methylthio)phenyl chromophore and the carboxylate binding group on the surfa
Alpha-(phenylalkyl) pyridinealkanol derivatives
-
, (2008/06/13)
This invention relates to novel α-(phenylalkyl) pyridinealkanol derivatives useful in the treatment of diseases or disorders mediated by platelet-activating factor. This invention further relates to pharmaceutical compositions of such α-(phenylalkyl)pyridinealkanol derivatives.
